000293587 001__ 293587
000293587 005__ 20250729140717.0
000293587 0247_ $$2doi$$a10.1002/ijc.35183
000293587 0247_ $$2pmid$$apmid:39308420
000293587 0247_ $$2ISSN$$a0020-7136
000293587 0247_ $$2ISSN$$a1097-0215
000293587 0247_ $$2altmetric$$aaltmetric:168205107
000293587 037__ $$aDKFZ-2024-01910
000293587 041__ $$aEnglish
000293587 082__ $$a610
000293587 1001_ $$aDamerell, Victoria$$b0
000293587 245__ $$aCirculating tryptophan-kynurenine pathway metabolites are associated with all-cause mortality among patients with stage I-III colorectal cancer.
000293587 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000293587 3367_ $$2DRIVER$$aarticle
000293587 3367_ $$2DataCite$$aOutput Types/Journal article
000293587 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1733729270_17662
000293587 3367_ $$2BibTeX$$aARTICLE
000293587 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293587 3367_ $$00$$2EndNote$$aJournal Article
000293587 500__ $$a 2025 Feb 1;156(3):552-565
000293587 520__ $$aAlterations within the tryptophan-kynurenine metabolic pathway have been linked to the etiology of colorectal cancer (CRC), but the relevance of this pathway for prognostic outcomes in CRC patients needs further elucidation. Therefore, we investigated associations between circulating concentrations of tryptophan-kynurenine pathway metabolites and all-cause mortality among CRC patients. This study utilizes data from 2102 stage I-III CRC patients participating in six prospective cohorts involved in the international FOCUS Consortium. Preoperative circulating concentrations of tryptophan, kynurenine, kynurenic acid (KA), 3-hydroxykynurenine (HK), xanthurenic acid (XA), 3-hydroxyanthranilic acid (HAA), anthranilic acid (AA), picolinic acid (PA), and quinolinic acid (QA) were measured by liquid chromatography-tandem mass spectrometry. Using Cox proportional hazards regression, we examined associations of above-mentioned metabolites with all-cause mortality, adjusted for potential confounders. During a median follow-up of 3.2 years (interquartile range: 2.2-4.9), 290 patients (13.8%) deceased. Higher blood concentrations of tryptophan, XA, and PA were associated with a lower risk of all-cause mortality (per doubling in concentrations: tryptophan: HR = 0.56; 95%CI:0.41,0.76, XA: HR = 0.74; 95%CI:0.64,0.85, PA: HR = 0.76; 95%CI:0.64,0.92), while higher concentrations of HK and QA were associated with an increased risk of death (per doubling in concentrations: HK: HR = 1.80; 95%CI:1.47,2.21, QA: HR = 1.31; 95%CI:1.05,1.63). A higher kynurenine-to-tryptophan ratio, a marker of cell-mediated immune activation, was associated with an increased risk of death (per doubling: HR = 2.07; 95%CI:1.52,2.83). In conclusion, tryptophan-kynurenine pathway metabolites may be prognostic markers of survival in CRC patients.
000293587 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293587 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293587 650_7 $$2Other$$aall‐cause mortality
000293587 650_7 $$2Other$$acolorectal cancer
000293587 650_7 $$2Other$$akynurenines
000293587 650_7 $$2Other$$aprognosis
000293587 650_7 $$2Other$$atryptophan
000293587 7001_ $$aKlaassen-Dekker, Niels$$b1
000293587 7001_ $$aBrezina, Stefanie$$b2
000293587 7001_ $$aOse, Jennifer$$b3
000293587 7001_ $$aUlvik, Arve$$b4
000293587 7001_ $$00000-0002-9402-2029$$avan Roekel, Eline H$$b5
000293587 7001_ $$aHolowatyj, Andreana N$$b6
000293587 7001_ $$aBaierl, Andreas$$b7
000293587 7001_ $$aBöhm, Jürgen$$b8
000293587 7001_ $$aBours, Martijn J L$$b9
000293587 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000293587 7001_ $$ade Wilt, Johannes H W$$b11
000293587 7001_ $$aGrady, William M$$b12
000293587 7001_ $$aHabermann, Nina$$b13
000293587 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b14$$udkfz
000293587 7001_ $$aKeski-Rahkonen, Pekka$$b15
000293587 7001_ $$aLin, Tengda$$b16
000293587 7001_ $$aSchirmacher, Peter$$b17
000293587 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b18$$udkfz
000293587 7001_ $$aUlrich, Alexis B$$b19
000293587 7001_ $$avan Duijnhoven, Fränzel J B$$b20
000293587 7001_ $$aWarby, Christy A$$b21
000293587 7001_ $$aShibata, David$$b22
000293587 7001_ $$00000-0003-1079-2606$$aToriola, Adetunji T$$b23
000293587 7001_ $$aFigueiredo, Jane C$$b24
000293587 7001_ $$aSiegel, Erin M$$b25
000293587 7001_ $$aLi, Christopher I$$b26
000293587 7001_ $$00000-0002-9795-1528$$aGsur, Andrea$$b27
000293587 7001_ $$aKampman, Ellen$$b28
000293587 7001_ $$aSchneider, Martin$$b29
000293587 7001_ $$aUeland, Per M$$b30
000293587 7001_ $$aWeijenberg, Matty P$$b31
000293587 7001_ $$00000-0001-7641-059X$$aUlrich, Cornelia M$$b32
000293587 7001_ $$aKok, Dieuwertje E$$b33
000293587 7001_ $$aGigic, Biljana$$b34
000293587 7001_ $$aConsortium, FOCUS$$b35$$eCollaboration Author
000293587 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35183$$gp. ijc.35183$$n3$$p552-565$$tInternational journal of cancer$$v156$$x0020-7136$$y2025
000293587 8564_ $$uhttps://inrepo02.dkfz.de/record/293587/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Damerell%20-%20Circulating%20tryptophan%20kynurenine%20pathway%20metabolites%20are%20associated%20with.pdf
000293587 8564_ $$uhttps://inrepo02.dkfz.de/record/293587/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Damerell%20-%20Circulating%20tryptophan%20kynurenine%20pathway%20metabolites%20are%20associated%20with.pdf?subformat=pdfa$$xpdfa
000293587 909CO $$ooai:inrepo02.dkfz.de:293587$$pVDB
000293587 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000293587 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000293587 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000293587 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293587 9141_ $$y2024
000293587 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000293587 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000293587 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000293587 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000293587 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000293587 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000293587 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000293587 980__ $$ajournal
000293587 980__ $$aVDB
000293587 980__ $$aI:(DE-He78)C070-20160331
000293587 980__ $$aI:(DE-He78)C120-20160331
000293587 980__ $$aI:(DE-He78)HD01-20160331
000293587 980__ $$aUNRESTRICTED